Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

National Patient Safety Consortium: Learning from Large-Scale Collaboration.

Kossey S, Power C, Thomson L, Morris K, Maloney S, Fairclough L, Prowse D, Laeeque H.

Healthc Q. 2020 Feb;22(SP):10-26. doi: 10.12927/hcq.2020.26050.

PMID:
32049612
2.

Extracellular vesicles and asthma: A review of the literature.

Sangaphunchai P, Todd I, Fairclough LC.

Clin Exp Allergy. 2020 Mar;50(3):291-307. doi: 10.1111/cea.13562. Epub 2020 Feb 4. Review.

PMID:
31925972
3.

Life-threatening hypersensitivity pneumonitis secondary to e-cigarettes.

Nair N, Hurley M, Gates S, Davies P, Chen IL, Todd I, Fairclough L, Bush A, Bhatt JM.

Arch Dis Child. 2019 Nov 11. pii: archdischild-2019-317889. doi: 10.1136/archdischild-2019-317889. [Epub ahead of print]

PMID:
31712273
4.

Autoantibodies in chronic obstructive pulmonary disease: A systematic review.

Byrne R, Todd I, Tighe PJ, Fairclough LC.

Immunol Lett. 2019 Oct;214:8-15. doi: 10.1016/j.imlet.2019.08.007. Epub 2019 Aug 28. Review.

PMID:
31472176
5.

Mood and influenza vaccination in older adults: A randomized controlled trial.

Ayling K, Fairclough L, Buchanan H, Wetherell MA, Vedhara K.

Health Psychol. 2019 Nov;38(11):984-996. doi: 10.1037/hea0000786. Epub 2019 Aug 5.

PMID:
31380684
6.

Towards a surrogate system to express human lipid binding TCRs.

Wang R, Pscheid R, Ghumra A, Kan LYL, Cochrane S, Fairclough L, Alcocer MJC.

Biotechnol Lett. 2019 Oct;41(10):1095-1104. doi: 10.1007/s10529-019-02713-2. Epub 2019 Jul 26.

PMID:
31346817
7.

Cigarette smoking differentially affects immunoglobulin class levels in serum and saliva: An investigation and review.

Tarbiah N, Todd I, Tighe PJ, Fairclough LC.

Basic Clin Pharmacol Toxicol. 2019 Nov;125(5):474-483. doi: 10.1111/bcpt.13278. Epub 2019 Jul 21.

PMID:
31219219
8.

Psychological interventions as vaccine adjuvants: A systematic review.

Vedhara K, Ayling K, Sunger K, Caldwell DM, Halliday V, Fairclough L, Avery A, Robles L, Garibaldi J, Welton NJ, Royal S.

Vaccine. 2019 May 31;37(25):3255-3266. doi: 10.1016/j.vaccine.2019.04.091. Epub 2019 May 6. Review.

PMID:
31068258
9.

Patients with tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) are hypersensitive to Toll-like receptor 9 stimulation.

Negm OH, Singh S, Abduljabbar W, Hamed MR, Radford P, McDermott EM, Drewe E, Fairclough L, Todd I, Tighe PJ.

Clin Exp Immunol. 2019 Sep;197(3):352-360. doi: 10.1111/cei.13306. Epub 2019 May 22.

PMID:
31009059
10.

Immunological and pathological effects of electronic cigarettes.

Chen IL, Todd I, Fairclough LC.

Basic Clin Pharmacol Toxicol. 2019 Sep;125(3):237-252. doi: 10.1111/bcpt.13225. Epub 2019 May 7. Review.

PMID:
30861614
11.

Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity.

Holmes J, Fairclough LC, Todd I.

Arch Dermatol Res. 2019 Apr;311(3):141-162. doi: 10.1007/s00403-019-01890-4. Epub 2019 Feb 23.

PMID:
30798353
12.

Tobacco smoke and nicotine suppress expression of activating signaling molecules in human dendritic cells.

Alkhattabi N, Todd I, Negm O, Tighe PJ, Fairclough LC.

Toxicol Lett. 2018 Dec 15;299:40-46. doi: 10.1016/j.toxlet.2018.09.002. Epub 2018 Sep 15.

PMID:
30227238
13.

Sustaining knowledge translation interventions for chronic disease management in older adults: protocol for a systematic review and network meta-analysis.

Tricco AC, Moore JE, Beben N, Brownson RC, Chambers DA, Dolovich LR, Edwards A, Fairclough L, Glasziou PP, Graham ID, Hemmelgarn BR, Holmes B, Isaranuwatchai W, Lachance CC, Legare F, McGowan J, Majumdar SR, Presseau J, Squires JE, Stelfox HT, Strifler L, Thompson K, Van der Weijden T, Veroniki AA, Straus SE.

Syst Rev. 2018 Sep 15;7(1):140. doi: 10.1186/s13643-018-0808-4.

14.

Accelerating surgical quality improvement in Ontario through a regional collaborative: a quality-improvement study.

Jackson T, Schramm D, Moloo H, Fairclough L, Maeda A, Beath T, Nathens A.

CMAJ Open. 2018 Aug 28;6(3):E353-E359. doi: 10.9778/cmajo.20170166. Print 2018 Jul-Sep.

15.

Measuring Vaccine Responses in the Multiplex Era.

Ayling K, Vedhara K, Fairclough L.

Methods Mol Biol. 2018;1781:327-340. doi: 10.1007/978-1-4939-7828-1_17.

PMID:
29705855
16.

Prophylactic Antibiotic Use in COPD and the Potential Anti-Inflammatory Activities of Antibiotics.

Huckle AW, Fairclough LC, Todd I.

Respir Care. 2018 May;63(5):609-619. doi: 10.4187/respcare.05943. Epub 2018 Feb 20. Review.

17.

Characterization of Behavioral, Signaling and Cytokine Alterations in a Rat Neurodevelopmental Model for Schizophrenia, and Their Reversal by the 5-HT6 Receptor Antagonist SB-399885.

Shortall SE, Negm OH, Fowler M, Fairclough LC, Tighe PJ, Wigmore PM, King MV.

Mol Neurobiol. 2018 Sep;55(9):7413-7430. doi: 10.1007/s12035-018-0940-0. Epub 2018 Feb 8.

18.

IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review.

Saniklidou AH, Tighe PJ, Fairclough LC, Todd I.

Arch Dermatol Res. 2018 Jan;310(1):11-28. doi: 10.1007/s00403-017-1789-1. Epub 2017 Oct 25. Review.

19.

Autoantibodies of IgM and IgG classes show differences in recognition of multiple autoantigens in chronic obstructive pulmonary disease.

Shindi R, Almehairi A, Negm OH, Kalsheker N, Gale NS, Shale DJ, Harrison TW, Bolton CE, John M, Todd I, Tighe PJ, Fairclough LC.

Clin Immunol. 2017 Oct;183:344-353. doi: 10.1016/j.clim.2017.09.020. Epub 2017 Sep 23.

PMID:
28951328
20.

Positive mood on the day of influenza vaccination predicts vaccine effectiveness: A prospective observational cohort study.

Ayling K, Fairclough L, Tighe P, Todd I, Halliday V, Garibaldi J, Royal S, Hamed A, Buchanan H, Vedhara K.

Brain Behav Immun. 2018 Jan;67:314-323. doi: 10.1016/j.bbi.2017.09.008. Epub 2017 Sep 18.

21.

A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.

Todd I, Negm OH, Reps J, Radford P, Figueredo G, McDermott EM, Drewe E, Powell RJ, Bainbridge S, Hamed M, Crouch S, Garibaldi J, St-Gallay S, Fairclough LC, Tighe PJ.

Pharmacol Res. 2017 Nov;125(Pt B):188-200. doi: 10.1016/j.phrs.2017.08.012. Epub 2017 Aug 30.

PMID:
28860008
22.

Peripheral killer cells do not differentiate between asthma patients with or without fixed airway obstruction.

Tubby C, Negm OH, Harrison T, Tighe PJ, Todd I, Fairclough LC.

J Asthma. 2017 Jun;54(5):456-466. doi: 10.1080/02770903.2016.1236941. Epub 2016 Oct 13.

PMID:
27736259
23.

The application of protein microarray assays in psychoneuroimmunology.

Ayling K, Bowden T, Tighe P, Todd I, Dilnot EM, Negm OH, Fairclough L, Vedhara K.

Brain Behav Immun. 2017 Jan;59:62-66. doi: 10.1016/j.bbi.2016.09.013. Epub 2016 Sep 14.

PMID:
27640078
24.

Multiple Circulating Cytokines Are Coelevated in Chronic Obstructive Pulmonary Disease.

Selvarajah S, Todd I, Tighe PJ, John M, Bolton CE, Harrison T, Fairclough LC.

Mediators Inflamm. 2016;2016:3604842. doi: 10.1155/2016/3604842. Epub 2016 Jul 25.

25.

Modifying Hofstee standard setting for assessments that vary in difficulty, and to determine boundaries for different levels of achievement.

Burr SA, Whittle J, Fairclough LC, Coombes L, Todd I.

BMC Med Educ. 2016 Jan 28;16:34. doi: 10.1186/s12909-016-0555-y.

26.

Tumour necrosis factor receptor I blockade shows that TNF-dependent and TNF-independent mechanisms synergise in TNF receptor associated periodic syndrome.

Fairclough LC, Stoop AA, Negm OH, Radford PM, Tighe PJ, Todd I.

Eur J Immunol. 2015 Oct;45(10):2937-44. doi: 10.1002/eji.201545769. Epub 2015 Aug 17.

27.

Ex vivo and in vitro production of pro-inflammatory cytokines in Blau syndrome.

Galozzi P, Negm O, Greco E, Alkhattabi N, Gava A, Sfriso P, Fairclough L, Todd I, Tighe P, Punzi L.

Reumatismo. 2015 Mar 31;66(4):277-84. doi: 10.4081/reumatismo.2014.772.

28.

ELISA in the multiplex era: potentials and pitfalls.

Tighe PJ, Ryder RR, Todd I, Fairclough LC.

Proteomics Clin Appl. 2015 Apr;9(3-4):406-22. doi: 10.1002/prca.201400130. Epub 2015 Mar 25. Review.

29.

Natural and disease-specific autoantibodies in chronic obstructive pulmonary disease.

Daffa NI, Tighe PJ, Corne JM, Fairclough LC, Todd I.

Clin Exp Immunol. 2015 Apr;180(1):155-63. doi: 10.1111/cei.12565.

30.

Development and validation of protein microarray technology for simultaneous inflammatory mediator detection in human sera.

Selvarajah S, Negm OH, Hamed MR, Tubby C, Todd I, Tighe PJ, Harrison T, Fairclough LC.

Mediators Inflamm. 2014;2014:820304. doi: 10.1155/2014/820304. Epub 2014 Oct 14.

31.

A pro-inflammatory signalome is constitutively activated by C33Y mutant TNF receptor 1 in TNF receptor-associated periodic syndrome (TRAPS).

Negm OH, Mannsperger HA, McDermott EM, Drewe E, Powell RJ, Todd I, Fairclough LC, Tighe PJ.

Eur J Immunol. 2014 Jul;44(7):2096-110. doi: 10.1002/eji.201344328. Epub 2014 Jun 10.

32.

Modifying the Hofstee method may overcome problems.

Todd I, Burr S, Whittle J, Fairclough L.

Med Teach. 2014 Apr;36(4):358-9. doi: 10.3109/0142159X.2014.887842. Epub 2014 Feb 18. No abstract available.

PMID:
24548113
33.

Canadian Cancer Risk Management Model: evaluation of cancer control.

Evans WK, Wolfson MC, Flanagan WM, Shin J, Goffin J, Miller AB, Asakawa K, Earle C, Mittmann N, Fairclough L, Oderkirk J, Fin├Ęs P, Gribble S, Hoch J, Hicks C, Omariba DW, Ng E.

Int J Technol Assess Health Care. 2013 Apr;29(2):131-9. doi: 10.1017/S0266462313000044. Epub 2013 Mar 20.

PMID:
23514623
34.

Differential activation of killer cells in the circulation and the lung: a study of current smoking status and chronic obstructive pulmonary disease (COPD).

Wang J, Urbanowicz RA, Tighe PJ, Todd I, Corne JM, Fairclough LC.

PLoS One. 2013;8(3):e58556. doi: 10.1371/journal.pone.0058556. Epub 2013 Mar 11.

35.

Utility, reliability and reproducibility of immunoassay multiplex kits.

Tighe P, Negm O, Todd I, Fairclough L.

Methods. 2013 May 15;61(1):23-9. doi: 10.1016/j.ymeth.2013.01.003. Epub 2013 Jan 16.

PMID:
23333412
36.

Accelerating knowledge to action: the pan-Canadian cancer control strategy.

Fairclough L, Hill J, Bryant H, Kitchen-Clarke L.

Curr Oncol. 2012 Apr;19(2):70-7. doi: 10.3747/co.19.1019.

37.

Optimizing community and stakeholder engagement in a merger of community health centres.

Cohen A, Fairclough L, Jass J.

Healthc Manage Forum. 2011 Winter;24(4):192-5.

PMID:
22256516
38.

Genome-wide analysis of gene expression during Xenopus tropicalis tadpole tail regeneration.

Love NR, Chen Y, Bonev B, Gilchrist MJ, Fairclough L, Lea R, Mohun TJ, Paredes R, Zeef LA, Amaya E.

BMC Dev Biol. 2011 Nov 15;11:70. doi: 10.1186/1471-213X-11-70.

39.

Immunological basis of reversible and fixed airways disease.

Tubby C, Harrison T, Todd I, Fairclough L.

Clin Sci (Lond). 2011 Oct;121(7):285-96. doi: 10.1042/CS20110062. Review.

PMID:
21651498
40.

The secreted integrin ligand nephronectin is necessary for forelimb formation in Xenopus tropicalis.

Abu-Daya A, Nishimoto S, Fairclough L, Mohun TJ, Logan MP, Zimmerman LB.

Dev Biol. 2011 Jan 15;349(2):204-12. doi: 10.1016/j.ydbio.2010.10.015. Epub 2010 Oct 23.

41.

Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients.

Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC.

Respir Res. 2010 Jun 11;11:76. doi: 10.1186/1465-9921-11-76.

42.

Regulation in chronic obstructive pulmonary disease: the role of regulatory T-cells and Th17 cells.

Lane N, Robins RA, Corne J, Fairclough L.

Clin Sci (Lond). 2010 Apr 20;119(2):75-86. doi: 10.1042/CS20100033. Review.

PMID:
20402669
43.

Quantitative validation and comparison of multiplex cytokine kits.

Richens JL, Urbanowicz RA, Metcalf R, Corne J, O'Shea P, Fairclough L.

J Biomol Screen. 2010 Jun;15(5):562-8. doi: 10.1177/1087057110362099. Epub 2010 Feb 22.

PMID:
20176857
44.

Altered effector function of peripheral cytotoxic cells in COPD.

Urbanowicz RA, Lamb JR, Todd I, Corne JM, Fairclough LC.

Respir Res. 2009 Jun 22;10:53. doi: 10.1186/1465-9921-10-53.

45.

Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease.

Richens JL, Urbanowicz RA, Lunt EA, Metcalf R, Corne J, Fairclough L, O'Shea P.

Respir Res. 2009 Apr 22;10:29. doi: 10.1186/1465-9921-10-29. Review.

46.

Allergen-driven suppression of thiol production by human dendritic cells and the effect of thiols on T cell function.

Hasan AA, Ghaemmaghami AM, Fairclough L, Robins A, Sewell HF, Shakib F.

Immunobiology. 2009;214(1):2-16. doi: 10.1016/j.imbio.2008.04.006. Epub 2008 Jun 20.

PMID:
19159822
47.

Killer cells in chronic obstructive pulmonary disease.

Fairclough L, Urbanowicz RA, Corne J, Lamb JR.

Clin Sci (Lond). 2008 Apr;114(8):533-41. doi: 10.1042/CS20070356. Review.

PMID:
18336369
48.

Xenopus laevis transgenesis by sperm nuclear injection.

Smith SJ, Fairclough L, Latinkic BV, Sparrow DB, Mohun TJ.

Nat Protoc. 2006;1(5):2195-203.

PMID:
17406457
49.

The detection of ADAM8 protein on cells of the human immune system and the demonstration of its expression on peripheral blood B cells, dendritic cells and monocyte subsets.

Richens J, Fairclough L, Ghaemmaghami AM, Mahdavi J, Shakib F, Sewell HF.

Immunobiology. 2007;212(1):29-38. Epub 2006 Sep 18.

PMID:
17270707
50.

The metrics of clinical trials.

Wright J, Fairclough L, Manzo J, Phippard L, Smuck B, Lacourciere J.

J Clin Oncol. 2005 Mar 1;23(7):1589-90; author reply 1590-1. No abstract available.

PMID:
15735144

Supplemental Content

Loading ...
Support Center